| The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells R Scherließ International journal of pharmaceutics 411 (1-2), 98-105, 2011 | 143 | 2011 |
| Preparation and purification of cationic solid lipid nanospheres--effects on particle size, physical stability and cell toxicity KHG Heydenreich AV, Westmeier R, Pedersen N, Poulsen HS Int J Pharm 254 (1), 83-87, 2003 | 132 | 2003 |
| Stabilisation of proteins via mixtures of amino acids during spray drying A Ajmera, R Scherließ International Journal of Pharmaceutics 463 (1), 98-107, 2014 | 103 | 2014 |
| Mucosal vaccination via the respiratory tract M Hellfritzsch, R Scherließ Pharmaceutics 11 (8), 375, 2019 | 102 | 2019 |
| In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations R Scherließ, S Buske, K Young, B Weber, T Rades, S Hook Vaccine 31 (42), 4812-4819, 2013 | 98 | 2013 |
| Mucoadhesive buccal films based on a graft co-polymer–A mucin-retentive hydrogel scaffold JF Alopaeus, M Hellfritzsch, T Gutowski, R Scherließ, A Almeida, ... European Journal of Pharmaceutical Sciences 142, 105142, 2020 | 92 | 2020 |
| Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity R Rietscher, M Schröder, J Janke, J Czaplewska, M Gottschaldt, ... European Journal of Pharmaceutics and Biopharmaceutics 102, 20-31, 2016 | 72 | 2016 |
| Particle engineering in dry powders for inhalation R Scherließ, S Bock, N Bungert, A Neustock, L Valentin European Journal of Pharmaceutical Sciences 172, 106158, 2022 | 70 | 2022 |
| Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations M Hertel, E Schwarz, M Kobler, S Hauptstein, H Steckel, R Scherließ International journal of pharmaceutics 535 (1-2), 59-67, 2018 | 66 | 2018 |
| DPI formulations for high dose applications–Challenges and opportunities R Scherließ, C Etschmann International journal of pharmaceutics 548 (1), 49-53, 2018 | 58 | 2018 |
| Nasal powder formulations: In-vitro characterisation of the impact of powders on nasal residence time and sensory effects M Trenkel, R Scherließ Pharmaceutics 13 (3), 385, 2021 | 57 | 2021 |
| Nasal formulations for drug administration and characterization of nasal preparations in drug delivery R Scherließ Therapeutic Delivery 11 (3), 183-191, 2020 | 57 | 2020 |
| Characterisation of nasal devices for delivery of insulin to the brain and evaluation in humans using functional magnetic resonance imaging J Wingrove, M Swedrowska, R Scherließ, M Parry, M Ramjeeawon, ... Journal of Controlled Release 302, 140-147, 2019 | 53 | 2019 |
| Carrier-based dry powder formulation for nasal delivery of vaccines utilizing BSA as model drug S Trows, R Scherließ Powder Technology 292, 223-231, 2016 | 45 | 2016 |
| Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate M Mönckedieck, J Kamplade, P Fakner, NA Urbanetz, P Walzel, H Steckel, ... International journal of pharmaceutics 524 (1-2), 351-363, 2017 | 42 | 2017 |
| Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment SH Westmeier R J Pharm Sci 97 (6), 2299-310, 2008 | 42 | 2008 |
| Simulation of particle size segregation in a pharmaceutical tablet press lab-scale gravity feeder C Hildebrandt, SR Gopireddy, R Scherließ, NA Urbanetz Advanced Powder Technology 29 (3), 765-780, 2018 | 41 | 2018 |
| The influence of high shear mixing on ternary dry powder inhaler formulations M Hertel, E Schwarz, M Kobler, S Hauptstein, H Steckel, R Scherließ International journal of pharmaceutics 534 (1-2), 242-250, 2017 | 41 | 2017 |
| Investigation of powder flow within a pharmaceutical tablet press force feeder–A DEM approach C Hildebrandt, SR Gopireddy, R Scherließ, NA Urbanetz Powder Technology 345, 616-632, 2019 | 39 | 2019 |
| Particle engineered mannitol for carrier-based inhalation–A serious alternative? N Hertel, G Birk, R Scherließ International journal of pharmaceutics 577, 118901, 2020 | 33 | 2020 |
